Advertorials
Contrast-based myopia control spectacle lenses slow myopia progression by up to 75% across diverse populations
Diffusion Optics Technology™ (DOT™) spectacle lenses slow average myopia progression by up to 75%, compared to single vision lenses, after 12 months of wear by North American and Chinese children
Advertorial content is paid for and produced by a sponsor, and is reviewed and edited by the OT team before publication.
01 September 2025
Working together with leading ocular research universities and hospitals around the world, SightGlass Vision has combined more than 10 years of research and development experience with multiple robust clinical trials to deliver DOT™ lenses, designed to control myopia progression in children from the age of six.
How do DOT™ lenses work?
It has been well-established that spending more time outdoors in natural environments (where contrast levels are low; see Figure 1a) can help delay the onset and may slow the progression of myopia,5-6 whereas spending more time indoors studying and in urban environments (where contrast levels are high; see Figure 1b) may be linked to accelerated myopia progression.5,7 DOT™ lenses are the first lenses designed to mimic more natural contrast to slow myopia progression.
Robust clinical trials in North America and China demonstrated that after the first year, average myopic progression was slowed by up to 75%.1,2* Now in its fifth year, the North American study has shown long-term safety and efficacy of DOT™ lenses, with no evidence of rebound effect 12 months after treatment cessation, meaning myopia control gains are retained after treatment ends.⁸

Fig 1a: Natural low contrast environment

Fig 1b: Artificial high contrast environment
How are DOT™ lenses different to other myopia control spectacle lenses?
DOT™ lenses do not incorporate positive power in the peripheral lens optics and instead incorporate thousands of light-scattering elements in the lens periphery to manage contrast levels. DOT™ lenses provide excellent visual experience, clinically equivalent to regular single-vision lenses.⁹

Real-world practice and clinical evidence
“Through years of prescribing DOT™ lenses to children in our practice, we’ve seen reliable outcomes in slowing myopia progression. This gives us confidence in the technology, and DOT™ lenses have become our preferred option for myopia control,” said Dr Kylvin Ho FIAO, optometrist.
What do children think?
93% of children say they love their glasses with DOT™ lenses¹⁰,¹¹ **. DOT™ lenses are as easy to adapt to as standard single-vision lenses, with 97% of children adapting within two to three days of wear.¹¹
“One million children have worn DOT™ lenses — a significant milestone for the company,” said Andrew Sedgwick, CEO of SightGlass Vision.
“Building on this success, we’re excited to be launching DOT™ spectacle lenses in the UK later this year.”
To find out more about the role of contrast in myopia control, register for OT’s upcoming webinar Seeing the Difference: Contrast Theory, Clinical Evidence, and Patient Conversations, presented by Kate Gifford.
Resources
Find out more about:
- DOT™ lenses & SightGlass Vision | Slow Down Myopia Progression in Children
- Real-world experience with DOT™ lenses
- New research insights 2024 summary.
Contact for further information:
†SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.
References
*Patient population aged six–10 years (North American study) and six–13 years (Chinese study).
**Proportion agreeing to “I love my DOT™ glasses” at the 30-day visit.
This figure is based on sales data and repurchase rates and reflects global usage across multiple regions.
- Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol. 2023;107:1709-1715.
- Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.
- Holden et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016;123(5);1036-1042
- Bullimore and Brennan. Myopia: An ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt 2023;43(1):116–121.
- Morgan et al. IMI Risk factors for myopia. Invest Ophthalmol. Vis. Sci 2021;62(5):3
- Eppenberger & Sturm. The Role of Time Exposed to Outdoor Light for Myopia Prevalence and Progression: A Literature Review. Clin Ophthalmol 2020;14:1875-1890.
- Biswas et al. The influence of the environment and lifestyle on myopia. J Physiol Anthropol 2024;43(1):7.
- Hill et al. Myopia progression one-year after cessation of contrast modulation spectacle lenses, presented at ARVO 2025.
- Wolffsohn et al. Visual impact of diffusion optic technology lenses for myopia control. Ophthalmic Physiol Opt 2024; 44: 1398–1406.
- SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n=256, 14 North American sites).
- SGV data on file 2023. CATHAY Efficacy and Safety Study (n=190, 5 Chinese sites). After 2–3 days of wearing the allocated spectacle lenses, the rate of adaptation was the same for DOT™ lenses and SV lenses (97% overall in each group).
